| Literature DB >> 22467342 |
Vadim Tchaikovski1, Gregory Y H Lip.
Abstract
The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22467342 DOI： 10.1007/s11906-012-0263-x
Source DB: PubMed Journal: Curr Hypertens Rep ISSN： 1522-6417 Impact factor: 5.369